Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017360 | 0.74 | KDM4E (0.43) | HSD17B10HPGDKDM4EALDH1A1ATM | |
| SCHEMBL22016504 | 0.71 | ATM (0.40) | ADORA2BRXFP1ATMNPC1 | |
| SCHEMBL22017688 | 0.70 | FEN1 (0.65) | ADORA2BALDH1A1L3MBTL1 | |
| SCHEMBL25407320 | 0.67 | HSD17B10 (0.46) | ADORA2BHSD17B10HPGDHTTATM | |
| SCHEMBL25406820 | 0.63 | MAPT (0.42) | ADORA2BHSD17B10HPGDHTTRXFP1 | |
| SCHEMBL10495854 | 0.63 | HSD17B10 (0.67) | ADORA2BHSD17B10HPGDHTTRXFP1 | |
| SCHEMBL10958621 | 0.63 | ADORA2B (0.69) | ADORA2BRXFP1 | |
| SCHEMBL9040192 | 0.63 | RXFP1 (0.47) | ADORA2BHSD17B10HPGDHTTRXFP1 | |
| SCHEMBL25408350 | 0.63 | ADORA2B (0.47) | ADORA2BHSD17B10HPGDHTTATM | |
| SCHEMBL30349777 | 0.63 | ADORA2B (0.47) | ADORA2BHSD17B10HPGDHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119383-A1 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | ITGB7, ITGB1, ITGA2B | ADORA2B 616/4885HSD17B10 3422/4885HPGD 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.